Assembly Biosciences, Inc. (ASMB)
Stock Price:
$15.35 USD
-0.20 (-1.29%)
Updated Oct 20, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
504.32M |
| Revenue (ttm) |
52.45M |
| Net Income (ttm) |
-71.46M |
| Shares Out |
32.85M |
| EPS (ttm) |
-2.31 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 20, 2020 |
| Last Price |
$15.35 |
| Previous Close |
$15.55 |
| Change ($) |
-0.20 |
| Change (%) |
-1.29% |
| Day's Open |
15.55 |
| Day's Range |
14.62 - 16.22 |
| Day's Volume |
308,960 |
| 52-Week Range |
10.23 - 27.84 |
More Stats
| Market Cap |
504.32M |
| Enterprise Value |
288.74M |
| Earnings Date (est) |
Nov 5, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
32.85M |
| Float |
30.63M |
| EPS (basic) |
-2.49 |
| EPS (diluted) |
-2.31 |
| FCF / Share |
-2.49 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
3.85M |
| Short Ratio |
13.09 |
| Short % of Float |
12.58% |
| Beta |
1.20 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
9.61 |
| PB Ratio |
1.90 |
| Revenue |
52.45M |
| Operating Income |
-75.79M |
| Net Income |
-71.46M |
| Free Cash Flow |
-87.94M |
| Net Cash |
215.58M |
| Net Cash / Share |
6.56 |
| Gross Margin |
-133.06% |
| Operating Margin |
-144.49% |
| Profit Margin |
-136.20% |
| FCF Margin |
-167.66% |
| ROA |
-17.27% |
| ROE |
-32.35% |
| ROIC |
-38.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (6)
| Buy |
5 |
| Overweight |
1 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$45.40*
(195.77% upside)
Low
30.0
Current: $15.35
High
74.0
Target: 45.40
*Average 12-month price target from 5 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 15.96 | 14.80 | 9.02 | - | - | - | - | - | - | - |
| Revenue Growth | 7.83% | 64.14% | - | - | - | - | - | - | - | - |
| Gross Profit | 15.96 | 14.80 | 9.02 | - | - | - | - | - | - | - |
| Operating Income | -103 | -92.74 | -52.23 | -45.28 | -29.66 | -23.96 | -19.60 | -24.86 | -34.00 | -4.77 |
| Net Income | -97.63 | -90.75 | -42.81 | -44.26 | -28.45 | -23.79 | -19.40 | -24.79 | -34.34 | -15.29 |
| Shares Outstanding | 26.26 | 22.80 | 17.75 | 17.23 | 15.70 | 7.00 | 3.88 | 2.55 | 1.92 | 0.12 |
| Earnings Per Share | -3.72 | -3.98 | -2.41 | -2.57 | -1.81 | -3.40 | -5.00 | -9.70 | -17.85 | -123.35 |
| Operating Cash Flow | -84.07 | -64.96 | 1.86 | -34.88 | -18.70 | -14.97 | -17.80 | -21.38 | -25.07 | -5.21 |
| Capital Expenditures | -1.55 | -0.34 | -0.87 | -0.15 | -0.06 | -0.15 | -0.01 | - | -0.01 | - |
| Free Cash Flow | -85.62 | -65.30 | 1.00 | -35.03 | -18.76 | -15.12 | -17.80 | -21.38 | -25.08 | -5.21 |
| Cash & Equivalents | 274 | 218 | 120 | 52.96 | 67.66 | 29.09 | 27.06 | 20.49 | 36.98 | 14.57 |
| Total Debt | 12.27 | - | - | - | - | - | - | - | - | 2.49 |
| Net Cash / Debt | 262 | 218 | 120 | 52.96 | 67.66 | 29.09 | 27.06 | 20.49 | 36.98 | 12.08 |
| Assets | 340 | 268 | 169 | 98.12 | 134 | 71.23 | 27.13 | 20.56 | 37.05 | 14.62 |
| Liabilities | 66.69 | 57.39 | 56.18 | 18.24 | 15.00 | 12.65 | 2.64 | 2.75 | 2.51 | 2.99 |
| Book Value | 273 | 211 | 113 | 79.88 | 119 | 58.57 | 24.49 | 17.81 | 34.53 | 11.63 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Assembly Biosciences, Inc. |
| Country |
United States |
| Employees |
139 |
| CEO |
John G. McHutchison |
Stock Information
| Ticker Symbol |
ASMB |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: ASMB |
| IPO Date |
December 17, 2010 |
Description
Assembly Biosciences operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome. It is involved in the development of core inhibitors that inhibit the functional activities of HBV core protein at various points in the viral lifecycle. The company's microbiome program consists of an integrated platform that includes the disease-targeted strain isolation, identification, characterization, and selection process for strain purification and growth under current good manufacturing practice conditions; and a licensed patented delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. Its product candidates include ABI-H0731 that is in Phase 2a clinical trials for the treatment of HBV; ABI-H2158, which is in Phase 1a/1b dose-ranging clinical study in the HBV-cure program; and ABI-H3733 that is in preclinical studies for the treatment of HBV. In addition, the company engages in the development of product candidates for various disease indications, such as Crohn's disease, irritable bowel syndrome, immune-mediated and metabolic disorders, and oncology by using its microbiome platform. It has a collaboration agreement with Allergan Pharmaceuticals International Limited for the development and commercialization of various microbiome gastrointestinal programs. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was founded in 2005 and is headquartered in South San Francisco, California.